Cargando…
The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center
BACKGROUND: Significant advances in multiple myeloma (MM) over the past 15 years led to exciting changes in the management of MM patients in China, which in turn brought about the early diagnoses, precise risk stratifications, and improved prognoses. METHODS: We summarized the dynamic changes in the...
Autores principales: | Yang, Yang, Li, Jing, Wang, Wenjing, Wang, Yawen, Maihemaiti, Aziguli, Ren, Liang, Lan, Tianwei, Zhou, Chi, Li, Panpan, Wang, Pu, Aihemaiti, Xianmuseye, Chen, Feifei, Xu, Tianhong, Xu, Jiadai, Liu, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166961/ https://www.ncbi.nlm.nih.gov/pubmed/36807775 http://dx.doi.org/10.1002/cam4.5737 |
Ejemplares similares
-
Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma
por: Li, Panpan, et al.
Publicado: (2023) -
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
por: Jiang, Jifeng, et al.
Publicado: (2020) -
High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients
por: Sun, Yifeng, et al.
Publicado: (2020) -
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
por: Larsen, Jeremy T., et al.
Publicado: (2015) -
Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma
por: Xu, Jiadai, et al.
Publicado: (2020)